At the most basic level, the answer is no – pregnant women should not use GlutaOne 1200 mg unless a qualified obstetrician or maternal‑fetal‑medicine specialist explicitly prescribes it and can monitor the therapy. The drug’s active ingredient, pharmaceutical‑grade L‑glutathione, is not listed on any major regulatory agency’s “safe‑in‑pregnancy” registry, and the published evidence to date does not support routine use during gestation.
GlutaOne 1200 mg is a sterile, injectable preparation of reduced L‑glutathione, marketed primarily for its antioxidant properties and, in some regions, for skin‑brightening regimens. The typical adult dosage ranges from 600 mg to 1200 mg, administered either intravenously (IV) or intramuscularly (IM) under medical supervision. Below is a quick reference table of the formulation and recommended adult dosing.
| Component | Amount per 5 mL vial | Typical Adult Dose | Route |
|---|---|---|---|
| L‑Glutathione (reduced form) | 1200 mg | 600–1200 mg | IV or IM |
| Sodium chloride | 0.9 % | — | — |
| Water for injection | qs ad 5 mL | — | — |
Regulatory stance and pregnancy labeling
Because glutathione is classified as a nutritional supplement rather than a prescription drug in many jurisdictions, regulatory agencies have not assigned it a formal pregnancy category. However, the lack of a specific “safe‑in‑pregnancy” designation carries an implicit warning.
| Agency | Pregnancy Classification | Labeling Statement |
|---|---|---|
| U.S. FDA | Not classified (no pregnancy category) | “Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.” |
| European Medicines Agency (EMA) | Unclassified | “Insufficient data; not recommended unless under medical supervision.” |
| Health Canada | Not listed | “Avoid use in pregnancy due to lack of safety data.” |
What the pharmacology tells us
Glutathione is the most abundant intracellular thiol, playing a central role in detoxifying reactive oxygen species (ROS), maintaining redox balance, and supporting immune function. During pregnancy, the maternal redox environment shifts to accommodate heightened metabolic demands; however, the extent to which exogenous glutathione crosses the placenta or influences fetal development remains unknown. Studies on placental perfusion have shown only trace amounts of reduced glutathione in the fetal circulation, suggesting limited transplacental transfer of the exogenous form.
Clinical evidence – human data
Prospective human trials evaluating glutathione supplementation in pregnant women are sparse. A 2022 double‑blind pilot study (n = 48) examined the effect of IV glutathione